Preillon et al., studying the actions of antagonistic antibody EOS-448 against TIGIT, showed several mechanisms that ensure the antitumor efficacy of specific proteins, namely the restoration of the functions of effector T-cells; the induction of antibody-dependent cellular cytotoxicity against regulatory T-cells, due to the high expression of TIGIT by cells of this subtype; and a direct cytotoxic effect on TIGIT+ tumor cells in cases of hematological diseases [127]. The gene discussed is TIGIT; the disease is hematologic disorder.